Eletriptan

The standard recommended starting dose for Eletriptan in adults is either 20 mg or 40 mg, taken at the first sign of a migraine headache. Clinical data suggests that the 40 mg dose may provide a higher rate of response, but it also carries a slightly higher risk of transient side effects. If the migraine returns after an initial response, a second dose may be taken, but it must be at least two hours after the first dose.

• Maximum Single Dose: 40 mg.
• Maximum Daily Dose: 80 mg in any 24-hour period.

If the first dose of Eletriptan does not provide any relief, a second dose should not be taken for the same attack, as it is unlikely to be effective. In such cases, patients should contact their healthcare provider to discuss alternative treatments.

Eletriptan is currently not approved for use in pediatric patients (children and adolescents under the age of 18). Clinical trials in adolescent populations (ages 12 to 17) failed to demonstrate a statistically significant difference between Eletriptan and placebo, likely due to a high placebo response rate common in pediatric migraine trials. Consequently, its safety and efficacy in this demographic have not been established.

Renal Impairment

No dosage adjustment is generally required for patients with mild to moderate renal impairment. However, because Eletriptan can increase blood pressure, caution is advised in patients with significant kidney disease. Eletriptan should be used with extreme caution, if at all, in patients with severe renal impairment.

Hepatic Impairment

For patients with mild to moderate hepatic impairment (Child-Pugh Categories A and B), the metabolism of Eletriptan may be slowed, but specific dose reductions are not always mandated. However, Eletriptan is contraindicated in patients with severe hepatic impairment (Child-Pugh Category C) because the drug is extensively metabolized by the liver, and blood levels could reach toxic concentrations.

Elderly Patients

Clinical studies of Eletriptan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range (20 mg), reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Eletriptan should be taken as soon as the migraine symptoms begin. It can be taken with or without food. The tablet should be swallowed whole with a full glass of water or other liquid. Do not crush, chew, or split the tablet, as this may affect the rate of absorption and the efficacy of the medication.

Storage is also vital; Eletriptan should be kept at room temperature (20°C to 25°C or 68°F to 77°F) in its original blister pack or container to protect it from moisture. Keep the medication out of reach of children and pets.

Eletriptan is taken only as needed for acute migraine attacks. It is not a daily medication. If you have a migraine and forget to take your dose, take it as soon as you remember. However, if you do not have a migraine, do not take a dose to 'prevent' a future attack. Never take two doses at once to make up for a missed one.

Signs of an Eletriptan overdose may include severe hypertension (high blood pressure), tachycardia (rapid heartbeat), chest pain, or other cardiovascular disturbances. Because Eletriptan has a half-life of 4 hours, monitoring for at least 20 hours is generally required following a significant overdose. There is no specific antidote for Eletriptan. In the event of an overdose, seek emergency medical attention immediately or contact a poison control center. Treatment is supportive, often involving gastric lavage and cardiovascular monitoring.

> Important: Follow your healthcare provider's dosing instructions strictly. Do not adjust your dose or frequency of use without medical guidance, as overusing triptans can lead to medication overuse headaches.

While Eletriptan is generally well-tolerated, some patients may experience mild to moderate side effects. The most frequently reported adverse reactions include:

• Asthenia (Weakness/Fatigue): Many patients report a feeling of general physical weakness or lack of energy shortly after taking the medication. This usually resolves within a few hours.
• Nausea: A feeling of sickness in the stomach. While nausea is a common symptom of migraine itself, Eletriptan can occasionally exacerbate this sensation.
• Somnolence (Drowsiness): A significant number of users feel sleepy or groggy. It is advised not to drive or operate heavy machinery until you know how Eletriptan affects you.
• Dizziness: A sensation of spinning or lightheadedness is common during the first two hours after administration.
• Xerostomia (Dry Mouth): A temporary reduction in saliva production.

These effects occur in a smaller percentage of the population but are still documented in clinical literature:

• Paresthesia: Tingling, 'pins and needles,' or numbness, often in the extremities or the face.
• Flushing: A sudden feeling of warmth or redness in the face and neck.
• Dyspepsia: Indigestion or discomfort in the upper abdomen.
• Pharyngitis: Sore throat or a sensation of tightness in the throat.
• Chest Tightness: A feeling of pressure or heaviness in the chest. While often benign and related to esophageal contraction, this must be distinguished from cardiac pain.

Rare but documented side effects include:

• Visual Disturbances: Blurred vision or temporary changes in sight.
• Tinnitus: Ringing in the ears.
• Hypertonia: Increased muscle tension or stiffness.
• Palpitations: Awareness of a fast or irregular heartbeat.

> Warning: Stop taking Eletriptan and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Myocardial Ischemia or Infarction: Symptoms include crushing chest pain, shortness of breath, or pain radiating to the jaw or left arm. Eletriptan can cause coronary artery vasospasm.
2. 2Serotonin Syndrome: A potentially life-threatening condition, especially when Eletriptan is taken with SSRIs or SNRIs. Symptoms include agitation, hallucinations, rapid heart rate, fever, muscle rigidity, and diarrhea.
3. 3Cerebrovascular Events: Stroke or Transient Ischemic Attack (TIA). Symptoms include sudden numbness or weakness (especially on one side of the body), sudden confusion, or trouble speaking.
4. 4Peripheral Vascular Ischemia: Numbness or coldness in the fingers and toes, or 'blue' extremities.
5. 5Gastrointestinal Ischemia: Severe abdominal pain and bloody diarrhea caused by reduced blood flow to the intestines.
6. 6Anaphylaxis: Severe allergic reaction characterized by swelling of the face/tongue, difficulty breathing, and hives.

The primary concern with long-term, frequent use of Eletriptan is Medication Overuse Headache (MOH). If Eletriptan is used for 10 or more days per month, it can actually cause headaches to become more frequent and more severe. This creates a cycle of dependency and chronic daily headache. Patients should track their usage and report frequent migraine recurrence to their doctor to discuss preventative therapies.

No FDA black box warnings are currently issued for Eletriptan. However, the FDA mandates a 'Warnings and Precautions' section regarding serious cardiovascular, cerebrovascular, and vasospastic reactions. These warnings are considered 'class warnings' for all triptan medications.

Report any unusual symptoms to your healthcare provider. If you experience side effects, you may also report them to the FDA at 1-800-FDA-1088.

Eletriptan is a potent vasoconstrictor and must be used with extreme caution. It is not a medication for 'everyday' headaches and should only be used when a clear diagnosis of migraine has been established by a healthcare professional. Before starting Eletriptan, patients must undergo a thorough medical history screening, particularly regarding cardiovascular health.

There are no FDA black box warnings for Eletriptan. However, the clinical warnings regarding its use in patients with undiagnosed coronary artery disease (CAD) are of paramount importance.

• Cardiovascular Risks: Eletriptan should not be given to patients with documented ischemic heart disease or coronary artery vasospasm (e.g., Prinzmetal’s angina). In patients with risk factors for CAD (e.g., hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history), a cardiovascular evaluation should be performed. If the patient is deemed at risk, the first dose of Eletriptan should ideally be administered in a medically supervised setting with ECG monitoring.
• Blood Pressure Elevation: Significant elevations in systemic blood pressure have been reported in patients with and without a history of hypertension. Blood pressure should be monitored, especially in those with pre-existing hypertension.
• Serotonin Syndrome: There is a risk of serotonin syndrome when triptans are combined with Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). Symptoms can range from mild (shivering and diarrhea) to severe (muscle rigidity, fever, and seizures).
• Anaphylaxis/Hypersensitivity: Rare cases of serious allergic reactions have occurred. Patients with a known hypersensitivity to eletriptan hydrobromide or any of the inactive ingredients must avoid this drug.
• Vasospastic Reactions: Beyond the heart, Eletriptan can cause vasospasm in the gastrointestinal tract and peripheral vascular system, leading to ischemia.

For most healthy patients, routine lab tests are not required specifically for Eletriptan use. However, for those with underlying conditions, the following may be monitored:

• Blood Pressure: Regular checks, especially during the first few weeks of therapy.
• Cardiac Function: Periodic ECGs for patients with multiple cardiovascular risk factors.
• Liver Function: Baseline liver enzymes for patients with suspected hepatic impairment.

Eletriptan commonly causes somnolence (drowsiness) and dizziness. Migraine itself often causes cognitive impairment and light sensitivity. Therefore, patients are strongly advised not to drive, operate heavy machinery, or engage in hazardous activities until the migraine has resolved and the effects of the medication have worn off.

Alcohol is a known migraine trigger for many individuals. Furthermore, alcohol can increase the sedative effects of Eletriptan, leading to profound drowsiness or impaired coordination. It is generally recommended to avoid alcohol consumption during a migraine attack and while Eletriptan is in your system.

There is no physical 'withdrawal' syndrome associated with stopping Eletriptan if it is used occasionally as prescribed. However, if the drug has been overused (leading to Medication Overuse Headache), stopping the drug may cause a temporary 'rebound' increase in headache frequency. In such cases, a doctor-supervised tapering schedule or a 'bridge' therapy with other medications may be necessary.

> Important: Discuss all your medical conditions, especially heart, liver, or kidney problems, with your healthcare provider before starting Eletriptan.

Eletriptan has several critical drug-drug interactions that can lead to life-threatening complications:

• Potent CYP3A4 Inhibitors: Eletriptan is primarily metabolized by the CYP3A4 enzyme. Drugs that strongly inhibit this enzyme can dramatically increase Eletriptan levels in the blood (up to 6-fold increase). Eletriptan must not be used within 72 hours of taking:
• Ketoconazole and Itraconazole (antifungals)
• Clarithromycin and Erythromycin (macrolide antibiotics)
• Ritonavir, Nelfinavir, and Indinavir (HIV protease inhibitors)
• Nefazodone (antidepressant)
• Ergotamine-containing or Ergot-type medications: Combining Eletriptan with ergotamine, dihydroergotamine (DHE), or methysergide can cause additive, prolonged vasospastic reactions. These drugs must not be taken within 24 hours of each other.
• Other Triptans: Do not use Eletriptan within 24 hours of another triptan (e.g., sumatriptan, rizatriptan, zolmitriptan) due to the risk of excessive vasoconstriction.

• SSRIs and SNRIs: Medications like fluoxetine, sertraline, venlafaxine, and duloxetine increase serotonin levels. Combining them with Eletriptan increases the risk of Serotonin Syndrome. If co-administration is clinically necessary, the patient should be observed closely, particularly during treatment initiation and dose increases.
• MAO Inhibitors: Unlike some other triptans, Eletriptan is not primarily metabolized by Monoamine Oxidase A (MAO-A). Therefore, the interaction is less severe than with sumatriptan. However, caution is still advised when using Eletriptan in patients taking MAOIs due to the general risk of serotonergic overload.

• Propranolol: Propranolol can slightly increase the Cmax and AUC of Eletriptan, though this is usually not clinically significant for most patients. However, monitor for increased side effects.

• Grapefruit Juice: Grapefruit is a known inhibitor of CYP3A4. While not as potent as ketoconazole, consuming large amounts of grapefruit juice while taking Eletriptan may increase the drug's concentration in the blood, potentially increasing the risk of side effects.
• High-Fat Meals: As noted in the PK section, high-fat meals can increase absorption by about 25%. While not dangerous, it may slightly alter the onset of action.

• St. John's Wort: This herbal supplement can affect serotonin levels and may induce CYP3A4 enzymes. Its use with Eletriptan should be avoided or closely monitored due to the risk of serotonin syndrome or reduced Eletriptan efficacy.
• 5-HTP / L-Tryptophan: These supplements are precursors to serotonin and can increase the risk of serotonin syndrome when combined with triptans.

Eletriptan is not known to interfere significantly with common clinical laboratory tests. However, always inform your laboratory technician and doctor about all medications you are taking.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. The 72-hour rule for CYP3A4 inhibitors is a critical safety requirement.

Eletriptan must NEVER be used in patients with the following conditions:

1. 1Ischemic Heart Disease: This includes patients with a history of myocardial infarction (heart attack), angina pectoris (chest pain), or documented silent ischemia. Eletriptan causes vasoconstriction of the coronary arteries, which could trigger a heart attack in these patients.
2. 2Coronary Artery Vasospasm: Including Prinzmetal’s variant angina. The drug's mechanism directly opposes the need for vessel dilation in these patients.
3. 3Wolff-Parkinson-White Syndrome: Or other arrhythmias associated with cardiac accessory conduction pathway disorders.
4. 4History of Stroke or TIA: Due to the risk of cerebrovascular vasospasm.
5. 5Peripheral Vascular Disease (PVD): Including ischemic bowel disease, as Eletriptan can further restrict blood flow to the limbs and organs.
6. 6Uncontrolled Hypertension: Eletriptan can acutely raise blood pressure, which could lead to a hypertensive crisis in those with already high levels.
7. 7Severe Hepatic Impairment: Patients with Child-Pugh Category C disease cannot properly metabolize the drug, leading to toxic accumulation.
8. 8Recent Use of Other Vasoconstrictors: Use within 24 hours of ergot-type medications or other 5-HT1 agonists.
9. 9Recent Use of CYP3A4 Inhibitors: Use within 72 hours of potent CYP3A4 inhibitors.

These conditions require a careful risk-benefit analysis by a physician:

• Controlled Hypertension: Requires monitoring of BP during use.
• Postmenopausal Women and Men over 40: Due to the higher statistical likelihood of undiagnosed cardiovascular disease.
• Smokers: High risk for underlying CAD.

Patients who have had an anaphylactic or severe allergic reaction to other triptans (like sumatriptan or rizatriptan) may have a cross-sensitivity to Eletriptan. While the chemical structures differ slightly, the pharmacological class is the same, and caution is warranted.

> Important: Your healthcare provider will evaluate your complete medical history, including a possible 'stress test' for your heart, before prescribing Eletriptan.

Eletriptan is classified under the former FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown developmental toxicity (decreased fetal body weight and increased incidences of skeletal variations) at doses that were also maternally toxic. Eletriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are pregnant or planning to become pregnant, discuss alternative migraine management strategies with your obstetrician and neurologist.

Eletriptan is excreted in human breast milk. In a study of 8 women, the average total amount of drug excreted in milk over 24 hours was approximately 0.02% of the dose. While this is a small amount, the effects on the nursing infant are not fully known. To minimize exposure, some healthcare providers suggest waiting 24 hours after taking a dose before resuming breastfeeding, during which time milk can be expressed and discarded.

Safety and effectiveness in pediatric patients under 18 years of age have not been established. As previously mentioned, clinical trials in adolescents did not show a benefit over placebo. Use in children is generally discouraged unless specifically directed by a pediatric neurologist in a specialized setting.

Patients over the age of 65 are at a higher risk for cardiovascular events, including hypertension and ischemic heart disease. Pharmacokinetic studies have shown that the half-life of Eletriptan may be slightly longer in the elderly (about 5-6 hours vs. 4 hours in younger adults). Because of the increased risk of side effects and underlying health conditions, Eletriptan is often avoided in the geriatric population in favor of safer alternatives.

In patients with mild to moderate renal impairment, the AUC of Eletriptan is slightly increased, but not to a degree that requires routine dose adjustment. However, because the drug can increase blood pressure, patients with renal disease should have their blood pressure monitored closely. Eletriptan should be avoided in patients with severe renal failure requiring dialysis.

The liver is the primary site of Eletriptan metabolism. In subjects with moderate hepatic impairment, the AUC and half-life are increased. While no dose adjustment is strictly required for mild-to-moderate impairment, the drug is contraindicated in severe hepatic impairment (Child-Pugh C).

> Important: Special populations require individualized medical assessment. Always inform your doctor if you fall into any of these categories before taking your first dose.

Eletriptan is a selective agonist for the 5-HT1B, 5-HT1D, and 5-HT1F serotonin receptors. It has very little affinity for 5-HT2, 5-HT3, or alpha-adrenergic, dopaminergic, or muscarinic receptors. Its primary action is to bind to 5-HT1B receptors on intracranial blood vessels, causing them to constrict. Simultaneously, it binds to 5-HT1D receptors on the sensory nerve endings of the trigeminal system, which inhibits the release of pro-inflammatory neuropeptides. This dual action addresses both the vascular and neural components of a migraine attack.

The onset of action for Eletriptan is approximately 30 to 60 minutes, with peak effects occurring around 2 hours. The duration of effect is typically sufficient to cover the length of a standard migraine attack, though recurrence can occur in some patients within 24 hours. Eletriptan does not appear to cause significant tolerance when used occasionally, but frequent use can lead to the downregulation of serotonin receptors, contributing to medication overuse headache.

| Parameter | Value |

|---|---|

| Bioavailability | ~50% |

| Protein Binding | ~85% |

| Half-life | ~4 hours |

| Tmax | 1.5 - 2 hours |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Fecal (~81%), Renal (~9%) |

• Molecular Formula: C22H26N2O2S (as free base)
• Molecular Weight: 382.52 g/mol (free base); 463.43 g/mol (hydrobromide salt)
• Solubility: Freely soluble in water.
• Structure: Eletriptan is a pyrrolidinylmethyl-indole derivative. It contains a sulfonyl group which contributes to its specific binding profile and lipophilicity.

Eletriptan belongs to the 'Triptan' class of medications (selective 5-HT1B/1D receptor agonists). Related medications include sumatriptan (Imitrex), rizatriptan (Maxalt), zolmitriptan (Zomig), naratriptan (Amerge), almotriptan (Axert), and frovatriptan (Frova). Among these, Eletriptan is noted for its high potency and relatively fast onset of action.